Product image of Infanrix-Ipv (Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid) supplied by GNH India

Infanrix-Ipv

Active Ingredient:
Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid
Origin:
EU

Infanrix-Ipv (Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid)

Pertussis Toxoid, Pertactin, the active ingredient in Infanrix-Ipv, is a vaccine presented as a vaccine formulation for intramuscular use. It prevents pertussis (whooping cough) in infants and children.\n\nGNH India supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and health‑care providers worldwide, ensuring quality‑controlled distribution and regulatory compliance.

Manufacturer / TM Owner

Glaxosmithkline Biologicals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Infanrix-Ipv is a pertussis vaccine used to protect against Bordetella pertussis infection.\n\n- Pertussis (whooping cough): provides active immunity that reduces the risk of infection and severe disease in infants and children.\n- Infant immunisation schedule: contributes to the recommended primary series for early childhood protection.\n- Community health programs: supports herd immunity to lower overall pertussis transmission in the population.

How It Works

  • Infanrix-Ipv contains pertussis toxoid and pertactin antigens adsorbed onto aluminium hydroxide, an adjuvant that enhances immune recognition. After intramuscular injection, antigen‑presenting cells process the proteins, stimulating B‑cell and T‑cell responses that lead to the production of specific antibodies against Bordetella pertussis, thereby conferring protective immunity.

Side Effects

  • Common Side Effects:\n- Injection site pain: mild to moderate discomfort at the injection site.\n- Redness or swelling: localized erythema or edema.\n- Fever: low‑grade temperature rise within 24‑48 hours.\n- Irritability or fussiness: especially in infants.\n- Loss of appetite: temporary decrease in feeding.\n\nSerious or Rare Side Effects:\n- Anaphylaxis: severe allergic reaction requiring immediate medical attention.\n- Seizures: rare neurologic events post‑vaccination.\n- High fever: temperature above 40°C that persists.\n- Prolonged crying: excessive crying lasting more than three hours.\n- Hypotonic‑hyporesponsive episode: transient loss of muscle tone in infants.

Precautions & Warnings

  • Infanrix-Ipv should be administered only after evaluating the individual's health status.\n\n- Allergy screening: avoid in persons with known hypersensitivity to any vaccine component.\n- Acute illness: postpone vaccination if the patient has a moderate or severe febrile illness.\n- Immunocompromised patients: assess risk‑benefit, as response may be reduced.\n- Concomitant vaccines: follow recommended intervals when co‑administering with live vaccines.\n- Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

  • Vaccination with Infanrix-Ipv may be influenced by other medical products.\n\nMajor Interactions (Avoid):\n- Live attenuated vaccines: avoid administration within four weeks before or after Infanrix-Ipv.\n- Immunoglobulin therapy: concurrent use may diminish vaccine‑induced immunity.\n\nModerate Interactions (Monitor Closely):\n- Antipyretics before vaccination: may blunt antibody response; use only after vaccination if needed.\n- Systemic corticosteroids: may reduce immunogenicity, monitor antibody levels.\n- Blood products: transfusions within two weeks may interfere with vaccine effectiveness.

Frequently Asked Questions

Infanrix-Ipv is a preventive vaccine indicated for the immunisation of infants and children against pertussis, also known as whooping cough. It helps the immune system develop protection by exposing it to pertussis toxoid and pertactin antigens, reducing the risk of infection and severe disease.

The pertussis toxoid and pertactin antigens are adsorbed onto aluminium hydroxide, which acts as an adjuvant. After intramuscular injection, these antigens are taken up by antigen‑presenting cells, stimulating B‑cell and T‑cell responses that generate specific antibodies against Bordetella pertussis, providing protective immunity.

The dosage and schedule of Infanrix-Ipv are determined by the prescribing healthcare professional based on national immunisation guidelines and the patient’s age. The prescriber will decide the appropriate volume and timing for each dose.

Infanrix-Ipv is generally not administered to pregnant women; instead, pertussis vaccination is recommended for pregnant women using a specific formulation (Tdap). Breastfeeding mothers may receive the vaccine if indicated, but they should consult their healthcare provider for personalized advice.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT